Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
August 08, 2023 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
August 08, 2023 07:58 ET
|
Recursion Pharmaceuticals
Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world’s...
Recursion to Participate in Upcoming Investor Conference
August 01, 2023 08:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
July 26, 2023 18:58 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at...
Recursion ने AI-सक्षम औषधि खोज में अभूतपूर्व फाउंडेशन मॉडल में तेज़ी लाने के लिए NVIDIA से सहयोग और $50 मिलियन के निवेश की घोषणा की
July 13, 2023 02:51 ET
|
Recursion Pharmaceuticals
साल्ट लेक सिटी, टोरंटो और मॉन्ट्रियल, July 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), औषधि खोज को औद्योगिक बनानेवाली एक अग्रणी क्लिनिकल स्टेज TechBio कंपनी ने, आज NVIDIA द्वारा $50...
Recursion anuncia colaboración e inversión de $ 50 millones de NVIDIA para acelerar modelos fundacionales innovadores en descubrimiento de fármacos habilitados para IA
July 13, 2023 02:51 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY y TORONTO y MONTREAL, July 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), una empresa líder de biotecnología en etapa clínica con la decodificación de biología para...
Recursion kündigt Zusammenarbeit und Investition in Höhe von 50 Millionen USD von NVIDIA zur Beschleunigung bahnbrechender Modelle für die KI-gestützte Wirkstoffforschung an
July 13, 2023 02:51 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, TORONTO und MONTRÉAL, July 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), ein führendes, im klinischen Stadium tätiges TechBio-Unternehmen, das die Biologie dekodiert,...
Recursion annonce sa collaboration avec NVIDIA qui investit 50 millions de dollars pour l'accélération de la mise au point de d'innovants modèles de base dans la découverte de médicaments basée sur l'IA
July 13, 2023 02:51 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, TORONTO et MONTRÉAL, 13 juill. 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), société biotechnologique au stade clinique chef de file dans le décodage biologique pour...
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
July 12, 2023 08:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery,...
Recursion célèbre l'ouverture de son siège canadien à Toronto avec des représentants du gouvernement et de l'écosystème biotechnologique
July 11, 2023 14:00 ET
|
Recursion Pharmaceuticals
TORONTO, 11 juill. 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), une société chef de file spécialisée dans la biotechnologie en stade clinique qui décode les données biologiques afin...